Voyager Earnings Beat, But Revenue Plunges 39%

Voyager Therapeutics reported fiscal 2026 Q2 earnings on Aug 07th, 2026. The company’s GAAP EPS of -$0.40 beat consensus estimates of -$0.48, marking an improvement in profitability. However, revenue of $3.17 million missed expectations by $1.39 million, reflecting a 39% year-over-year decline. Guidance remains aligned with clinical milestones, with no immediate adjustments to full-year outlooks provided.

Revenue

The total revenue of Voyager Therapeutics decreased by 39.1% to $3.17 million in 2026 Q2, down from $5.20 million in 2025 Q2. This decline was driven entirely by collaboration revenue, which accounted for the full $3.17 million total, indicating a complete reliance on partnership income during this period with no other distinct revenue streams contributing to the top line.

Earnings/Net Income

Voyager Therapeutics narrowed losses to $0.40 per share in 2026 Q2 from a loss of $0.57 per share in 2025 Q2 (29.8% improvement). Meanwhile, the company successfully narrowed its net loss to $-24.47 million in 2026 Q2, reducing losses by 26.7% compared to the $-33.38 million net loss reported in 2025 Q2. The EPS beat signals improved operational efficiency despite top-line pressure.

Price Action

The stock price of Voyager Therapeutics has climbed 6.51% during the latest trading day, has climbed 7.92% during the most recent full trading week, and has tumbled 12.33% month-to-date.

Post-Earnings Price Action Review

Following the earnings release, Voyager Therapeutics stock exhibited mixed momentum, rising 6.51% on the day of the report and gaining 7.92% over the subsequent full trading week. This short-term upside contrasts sharply with a 12.33% decline observed month-to-date, suggesting that while investors reacted positively to the earnings beat, broader market trends or prior valuation pressures continue to weigh on the stock. Trading volume stood at 421,035 shares, below the average of 646,793, indicating moderate interest. The stock closed at $3.13, trading within its 52-week range of $2.93 to $5.55, and remains below its 50-day and 200-day moving averages of $3.42 and $3.74, respectively.

CEO Commentary

Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, emphasized that tau represents a critical disease-modifying target in Alzheimer’s disease, citing recent third-party data as validation for this hypothesis. He highlighted the company’s strategic focus on advancing two tau-targeted programs toward clinical inflection points before year-end. Specifically, the anti-tau antibody VY7523 is expected to generate tau PET imaging efficacy data in Q4 2026, while the tau-targeted gene therapy VY1706 is anticipated to begin dosing in adults with early Alzheimer’s disease during the same quarter.

Guidance

Voyager expects VY1706 to begin dosing in adults with early Alzheimer’s disease in Q4 2026, following FDA IND clearance and Health Canada Clinical Trial Application approval. Concurrently, VY7523 is projected to deliver tau PET imaging efficacy data from its multiple ascending dose trial in Q4 2026. Partner Neurocrine Biosciences intends to initiate a clinical trial for NBIB-‘223 in Friedreich’s ataxia in H2 2026, pending successful FDA IND clearance. Looking ahead, initial acute safety data for VY1706 is anticipated in early 2027, with potential initial biomarker-based data expected in H2 2027, both pending enrollment. The company maintains a cash position of $148.8 million, providing a runway into 2028.

Additional News

Analyst sentiment toward Voyager Therapeutics remains divided, with HC Wainwright reaffirming a "buy" rating on July 20th, while Weiss Ratings maintained a "sell (d-)" rating on July 13th. Wall Street Zen downgraded the stock to "sell" in May. Despite this, the consensus rating stands as "Moderate Buy" with an average price target of $16.50. Institutional activity shows mixed signals: Jane Street Group LLC increased its stake by 92.6% in Q2, while Wexford Capital LP, CIBC Asset Management Inc., and Coldstream Capital Management Inc. initiated new positions. Hedge funds and institutions collectively own 48.03% of the company. These moves suggest cautious optimism among certain institutional players despite broader analyst skepticism.